Lokivetmab
Caninized monoclonal antibody targeting canine interleukin-31
Also known as: Cytopoint · lokivetmabum
Reviewed by the VetSheet Veterinary TeamUpdated Apr 5, 2026Evidence-based veterinary reference
Doses are a clinical reference for licensed veterinary professionals. Always confirm against the current label and the individual patient.
Dosing by species
🌎 NA — North America🌍 EU — Europe
Dogs
| Indication | Dose | Route | Frequency | Duration | Region |
|---|---|---|---|---|---|
| Pruritus associated with allergic dermatitis; atopic dermatitis | Minimum 1 mg/kg | SC | Once a month | Per individual response | 🌍 EU |
- Pruritus associated with allergic dermatitis; atopic dermatitis: Administer the entire contents (1 ml) of the vial; dose per the SPC weight chart. Do not use in dogs under 3 kg bodyweight. If no response after a second dose one month later, consider alternatives.
Doses are a clinical reference for licensed veterinary professionals. Always confirm against the current label and the individual patient.
Overview
Lokivetmab is a caninized monoclonal antibody (mAb) specifically designed to target and neutralize canine interleukin-31 (IL-31). It is primarily used for the treatment of clinical manifestations of atopic dermatitis in dogs, providing significant relief from pruritus (itching) and exhibiting anti-inflammatory properties.
Clinical Pearl: As a highly targeted biological therapy, lokivetmab does not have the broad immunosuppressive side effect profile associated with traditional therapies like corticosteroids or cyclosporine.
Mechanism of action
Lokivetmab specifically binds to and neutralizes canine interleukin-31 (IL-31), a key cytokine involved in the itch sensation.
- IL-31 → Blocked from binding to its co-receptor
- Cell signalling → Inhibited
- Result → Relief from atopic dermatitis-related pruritus and reduction of inflammation.
Safety & warnings
Contraindications
- Known hypersensitivity to the active substance or excipients
- Use in species other than dogs
Adverse effects
- Generally well tolerated
- Rare hypersensitivity reactions or injection site pain
Precautions
Clinical Pearl: Lokivetmab is a caninized antibody and should only be used in dogs. Do not use in cats or other species as it may induce an immune response or be ineffective. Monitor for rare hypersensitivity reactions following administration.
Monitoring
- Clinical response to pruritus and skin inflammation
- Signs of hypersensitivity post-injection
Pharmacokinetics
Half-life
Absorption
Well absorbed following subcutaneous administration.
Distribution
Distributed primarily in the vascular space and extracellular fluid, typical of monoclonal antibodies.
Metabolism
Degraded into small peptides and amino acids via normal catabolic pathways.
Elimination
Long elimination half-life allowing for monthly dosing.
Overdose
Overdoses are generally well tolerated due to the targeted nature of the monoclonal antibody, though the risk of immune-mediated reactions may theoretically increase. No specific antidote is required; treat symptomatically if adverse effects occur.
Available products
Formulations
- Injectable: 10 mg, 20 mg, 30 mg, 40 mg solution
Veterinary
- Cytopoint 10 mg solution for injection
- Cytopoint 20 mg solution for injection
- Cytopoint 30 mg solution for injection
- Cytopoint 40 mg solution for injection
Regulatory status
USDA regulated as a veterinary biologic.
POM-V
POM-V
No regulatory data for: 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR
Storage & stability
Store in a refrigerator (2°C - 8°C). Do not freeze. Protect from light.
Client information
Lokivetmab (Cytopoint) is a highly targeted biological therapy used to stop itching associated with allergic skin disease in dogs.
- It works by neutralizing the specific itch signal in your dog's body.
- It is given as an injection at the veterinary clinic.
- Relief from itching is usually seen within 24 hours and can last for 4 to 8 weeks.
Contact your veterinarian if the itching returns or if you notice any signs of an allergic reaction after the injection.
VetSheet drug reference is intended for licensed veterinary professionals as a clinical decision-support aid, not a substitute for professional judgement or the manufacturer’s current label.